Illumina Names Dr. Richard Klausner as Senior Vice President and Chief Medical Officer

Illumina Names Dr. Richard Klausner as Senior Vice President and Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)-- Illumina (NAS: ILMN) today announced it has appointed Dr. Richard Klausner as Senior Vice President and Chief Medical Officer. Dr. Klausner will report to President and Chief Executive Officer Jay Flatley and will lead Illumina's strategies for advancing genomics into clinical medicine and public health. He will also become part of Illumina's executive management team, which is responsible for directing all aspects of company strategy, planning and operations.

"Rick's expertise in molecular biology, his experience in life sciences, and his roles in global health policy make him uniquely suited to mobilize constituents around the use of genomics within medical practice," said Jay Flatley. "We are very excited about his vision and passion for ushering in a new era of precision medicine and his ability to work with clinicians, industry, government, and academia to help bring this vision to fruition."


Prior to joining Illumina, Dr. Klausner was managing partner of the venture capital firm, The Column Group. Previously, he held roles as Executive Director for Global Health at the Bill and Melinda Gates Foundation and as the eleventh director of the National Cancer Institute between 1995 and 2001. He has served as chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development, as well as a past president of the American Society of Clinical Investigation. He also has been Chairman of the National Science Education Standards Projects of the National Academy of Sciences.

Dr. Klausner is well known for his work in cell and molecular biology, and is the author of more than 300 scientific articles and several books, in addition to receiving numerous awards and honors. He has served as an Advisor to the Presidents of the Academies for counter-terrorism, as a Liaison to the White House Office of Science & Technology Policy, and as a Chief Strategy Advisor for USAID. He currently chairs the International Advisory Board for Samsung, is the Chairman of Audax Health, and previously chaired the Strategic Oversight Council of Sanofi. He is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. Dr. Klausner holds an M.D. from Duke Medical School.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.



Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Illumina Names Dr. Richard Klausner as Senior Vice President and Chief Medical Officer originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.